Leo As Patent-Cliff Exposure & CMS Drug Spending Portfolio

Leo As (US): 7 reconciled FDA prescription therapies (5.0% 2025 to 2030 cliff risk), $116.4M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure5.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$116.4M
2024 Medicare Part D Spend$63.7M
2024 Medicaid Spend$52.7M
California HCAI SB 17 Filings4 WAC filings (max 21.5% 2-yr change)